Closely held Unnatural Products (UNP) has announced the appointment of Neera Ravindran, MD, MBA, as chief financial officer (CFO).
Dr. Ravindran brings more than 20 years of deep public markets and private company experience, with a demonstrated ability to raise capital, to UNP as the company scales for its next stage of growth. In her role, she will lead UNP’s financial strategy and operations, including capital planning, competitive analysis, and investor relations.
In addition, she will support business development and execution of corporate strategy as the company advances programs from its macrocyclic peptide pipeline across multiple disease areas toward clinical investigation.
Previously, Dr. Ravindran served as CFO of Kriya Therapeutics, leading its $270 million Series C financing, scaling the finance organization, and building the financial foundation to support the company’s growth. Prior to joining Kriya, she served as VP and head of investor relations at Vir Biotechnology, where she helped drive the company’s growth from under $2 billion to $7 billion in market capitalization, including a successful $345 million public stock offering.
Dr. Ravindran added, “UNP has built the leading platform for macrocyclic peptides and established four validating partnerships across multiple disease areas in just a few years. As this field continues to build momentum, I am thrilled to join Cameron, Josh, and our exceptional team, strengthen UNP’s foundation, and equip this organization with the resources to keep chasing the targets nobody else has been able to reach.”
